JP7537074B2 - Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 - Google Patents

Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 Download PDF

Info

Publication number
JP7537074B2
JP7537074B2 JP2018559205A JP2018559205A JP7537074B2 JP 7537074 B2 JP7537074 B2 JP 7537074B2 JP 2018559205 A JP2018559205 A JP 2018559205A JP 2018559205 A JP2018559205 A JP 2018559205A JP 7537074 B2 JP7537074 B2 JP 7537074B2
Authority
JP
Japan
Prior art keywords
tsp1
htra1
peptide
inflammation
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018559205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521963A5 (enExample
JP2019521963A (ja
Inventor
セヌラウブ，フロライン
ハウセット，ミシェル
グイロンニーウ，グザビエ
サヘル，ホセ－アラン
カロヤン，フィリップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2019521963A publication Critical patent/JP2019521963A/ja
Publication of JP2019521963A5 publication Critical patent/JP2019521963A5/ja
Priority to JP2022035726A priority Critical patent/JP2022078244A/ja
Priority to JP2023180474A priority patent/JP2023179752A/ja
Application granted granted Critical
Publication of JP7537074B2 publication Critical patent/JP7537074B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018559205A 2016-05-10 2017-05-10 Ｃｄ４７を活性化する作用物質およびその炎症治療における使用 Active JP7537074B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022035726A JP2022078244A (ja) 2016-05-10 2022-03-08 Ｃｄ４７を活性化する作用物質およびその炎症治療における使用
JP2023180474A JP2023179752A (ja) 2016-05-10 2023-10-19 Ｃｄ４７を活性化する作用物質およびその炎症治療における使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16169072 2016-05-10
EP16169072.2 2016-05-10
EP17154452.1 2017-02-02
EP17154452 2017-02-02
PCT/EP2017/061151 WO2017194586A1 (en) 2016-05-10 2017-05-10 Agents that activate cd47 and their use in the treatment of inflammation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022035726A Division JP2022078244A (ja) 2016-05-10 2022-03-08 Ｃｄ４７を活性化する作用物質およびその炎症治療における使用
JP2023180474A Division JP2023179752A (ja) 2016-05-10 2023-10-19 Ｃｄ４７を活性化する作用物質およびその炎症治療における使用

Publications (3)

Publication Number Publication Date
JP2019521963A JP2019521963A (ja) 2019-08-08
JP2019521963A5 JP2019521963A5 (enExample) 2020-05-07
JP7537074B2 true JP7537074B2 (ja) 2024-08-21

Family

ID=58772857

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018559205A Active JP7537074B2 (ja) 2016-05-10 2017-05-10 Ｃｄ４７を活性化する作用物質およびその炎症治療における使用
JP2022035726A Pending JP2022078244A (ja) 2016-05-10 2022-03-08 Ｃｄ４７を活性化する作用物質およびその炎症治療における使用
JP2023180474A Pending JP2023179752A (ja) 2016-05-10 2023-10-19 Ｃｄ４７を活性化する作用物質およびその炎症治療における使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022035726A Pending JP2022078244A (ja) 2016-05-10 2022-03-08 Ｃｄ４７を活性化する作用物質およびその炎症治療における使用
JP2023180474A Pending JP2023179752A (ja) 2016-05-10 2023-10-19 Ｃｄ４７を活性化する作用物質およびその炎症治療における使用

Country Status (5)

Country Link
US (1) US11142548B2 (enExample)
EP (1) EP3454884B1 (enExample)
JP (3) JP7537074B2 (enExample)
CA (1) CA3023802C (enExample)
WO (1) WO2017194586A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3023802C (en) * 2016-05-10 2025-02-04 Inserm (Institut De La Sante Et De La Recherche Medicale) ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION
US20210052543A1 (en) 2018-01-09 2021-02-25 Brigham Young University Compositions and Methods for Treating Pain with Wogonin
WO2022113887A1 (ja) * 2020-11-27 2022-06-02 京都府公立大学法人 炎症性網膜疾患の判定方法、炎症性網膜疾患治療剤、及び炎症性網膜疾患治療剤のスクリーニング方法
WO2022232001A1 (en) * 2021-04-26 2022-11-03 President And Fellows Of Harvard College Cd47 compositions and methods for the treatment of degenerative ocular diseases
CN116831988A (zh) * 2023-06-13 2023-10-03 南京鼓楼医院 一种载肽模拟物pkhb1的脂质体眼用制剂及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012531893A (ja) 2009-06-29 2012-12-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム アルギナーゼ製剤および方法
US20140127269A1 (en) 2012-02-13 2014-05-08 The Schepens Eye Research Institute, Inc. Anti-Inflammatory Peptide Derived From Thrombospondin-1 and Uses Thereof
WO2015100113A2 (en) 2013-12-23 2015-07-02 Memorial Sloan-Kettering Cancer Center Methods and compositions for treating cancer using peptide nucleic acid-based agents
JP2015520178A (ja) 2012-06-06 2015-07-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 癌の処置における使用のための方法及び医薬的組成物
WO2016044383A1 (en) 2014-09-17 2016-03-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 antibodies (b7h3)
WO2016061133A1 (en) 2014-10-14 2016-04-21 Riptide Bioscience, Inc. Peptides having anti-inflammatory properties

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US6001962A (en) 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
CA2226962A1 (en) * 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
US6846637B1 (en) 1998-06-18 2005-01-25 Imed Ab Fas peptides and antibodies for modulating apoptosis
EP2479284B1 (en) 2006-07-13 2017-09-20 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
CA2747678A1 (en) * 2008-12-19 2010-06-24 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
WO2011137363A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
ES2616010T3 (es) 2010-05-14 2017-06-09 The Board Of Trustees Of The Leland Stanford Junior University Anticuerpos monoclonales humanizados y quiméricos a CD47
US10004780B2 (en) 2012-10-17 2018-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD)
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
FR3036620B1 (fr) * 2015-05-27 2017-09-01 Inst Biophytis Utilisation de 3-desoxyanthocyanidines pour le traitement de maladies oculaires
CA3023802C (en) * 2016-05-10 2025-02-04 Inserm (Institut De La Sante Et De La Recherche Medicale) ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012531893A (ja) 2009-06-29 2012-12-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム アルギナーゼ製剤および方法
US20140127269A1 (en) 2012-02-13 2014-05-08 The Schepens Eye Research Institute, Inc. Anti-Inflammatory Peptide Derived From Thrombospondin-1 and Uses Thereof
JP2015520178A (ja) 2012-06-06 2015-07-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 癌の処置における使用のための方法及び医薬的組成物
WO2015100113A2 (en) 2013-12-23 2015-07-02 Memorial Sloan-Kettering Cancer Center Methods and compositions for treating cancer using peptide nucleic acid-based agents
WO2016044383A1 (en) 2014-09-17 2016-03-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 antibodies (b7h3)
WO2016061133A1 (en) 2014-10-14 2016-04-21 Riptide Bioscience, Inc. Peptides having anti-inflammatory properties

Also Published As

Publication number Publication date
US20190225649A1 (en) 2019-07-25
EP3454884B1 (en) 2023-07-12
JP2023179752A (ja) 2023-12-19
JP2019521963A (ja) 2019-08-08
WO2017194586A1 (en) 2017-11-16
EP3454884A1 (en) 2019-03-20
US11142548B2 (en) 2021-10-12
CA3023802C (en) 2025-02-04
CA3023802A1 (en) 2017-11-16
JP2022078244A (ja) 2022-05-24

Similar Documents

Publication Publication Date Title
JP2023179752A (ja) Ｃｄ４７を活性化する作用物質およびその炎症治療における使用
US12454570B2 (en) Compositions and methods for growth factor modulation
Xi et al. IL-33 amplifies an innate immune response in the degenerating retina
CA2509241C (en) Use of serum amyloid p (sap) and related compositions for the suppression of fibrosis-related diseases
KR20180012856A (ko) 면역반응의 조절을 위한 방법 및 폴리펩타이드
US20210386837A1 (en) Active low molecular weight variants of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye
KR20180034518A (ko) 혈관신생 및 신혈관형성 관련 장애를 치료하는 방법
AU2018247928A1 (en) C4BP-based compounds for treating immunological diseases
JP2017505303A (ja) 網膜炎症の治療において使用するための薬剤
JP6397122B2 (ja) 血管新生関連疾患を治療するためのペプチドの使用
CN114901313A (zh) 急性期的视神经脊髓炎的预防或治疗剂
EP3394100B1 (en) Agents that inhibit the binding of cfh to cd11b/cd18 and uses thereof
CN118742563A (zh) 靶向usag-1分子的用于牙齿再生治疗的中和抗体
HK40048816A (en) Compositions and methods for growth factor modulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211015

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220308

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220308

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220322

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220512

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220517

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220610

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220614

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231019

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20231019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240722

R150 Certificate of patent or registration of utility model

Ref document number: 7537074

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150